The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events.

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Postmarketing reports indicate 17 serious adverse events have been reported in vaccine recipients 62 to 89 years old. Due to an ongoing investigation of serious adverse events, it is recommended ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

Federal drug safety officials have recommended pausing the use of a vaccine ... approved Ixchiq for the prevention of the disease in adults over 18 in November 2023. It uses a live, though ...

Those who experienced adverse effects of the vaccine were reported to be between the ages of 62 and 89. The FDA warned that Ixchiq, which contains a live, weakened version of chikungunya ...